Direct answer:The FDA launched a public watch board on bad cosmetics events on 12 September 2025, allowing the public to search and download reports. On March 11, 2026, the FDA updated that it was integrating the negative incident reporting system in several product areas into the FDA Adverse Event Monitoring System (AEMS). Enterprises can use watchboards as a regulatory information monitoring tool for information on products and events that appear in public reports.The nature of the documents, their current status and the enterprise’s recommendations are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. Public reporting is a signal and does not amount to FDA having verified or confirmed causality; AEMS integration does not mean that every data is mandatory.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Cosmetics responsible persons, manufacturers and importers; Team for product safety monitoring using open adverse event reports.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
The FDA launched a public watch board on bad cosmetics events on 12 September 2025, allowing the public to search and download reports. On March 11, 2026, the FDA updated that it was integrating the negative incident reporting system in several product areas into the FDA Adverse Event Monitoring System (AEMS). Enterprises can use watchboards as a regulatory information monitoring tool for information on products and events that appear in public reports.
The cosmetics panels include reports of serious adverse events from Responsible Person under MoCRA, and voluntary reports from consumers, medical professionals, beauty practitioners, etc. FDA indicates that the report is updated on a daily basis and can be retrieved by the user by product name, event term, severity, date or type of report.
AEMS is a cross-product reporting platform being deployed by FDA covering medical products, vaccines, instruments, tobacco, food, cosmetics and veterinary medicines. The objective of the Platform’s integration is to improve data quality and consistency, streamline reporting processes and enhance the monitoring of security signals. AEMS is a data management and monitoring platform that does not represent a FDA safety conclusion or approval decision for a product.
- Public reporting is seen as a market monitoring trail and internal checks are carried out in conjunction with products, formulations, batches and usage.
- Reconciling the reporting type, date, severity of the report, bearing in mind duplicated, incomplete or unverified information.
- Establish processes for the collection, assessment, upgrading and recording of consumer complaints and adverse events.
- Where applicable, reports of serious adverse events are dealt with by the legally responsible party in accordance with the FDA and do not replace the legal obligation with a public watchboard.
- References to public data clearly indicate their limitations and do not directly describe the number of reports as evidence of incidence or causality.
Key dates and transitional arrangements
- 2025-09-12:FDA has launched a public query board for bad cosmetics events.
- 2026-03-11:FDA Updates AEMS Integration Note.
- Sustained:The FDA indicates that the viewboard data are updated on a daily basis; This is not a new comment period or a uniform entry into force date.
The date of the post update is not the date of implementation of the statute; The frequency of updates to the information reported is based on the current viewer description of the FDA.
How can Chinese companies prepare?
- Establishment of a reporting signal review process; (b) Distinguishing mandatory reporting of serious adverse incidents from voluntary public reporting; Document product, batch, exposure and causation evidence.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- Public reporting is a signal and does not amount to FDA having verified or confirmed causality; AEMS integration does not mean that every data is mandatory.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
- FDA:FDA Launches Real-Time Adverse Event Reporting Dashboard for Cosmetic Products(2025-09-12; 2026-03-11 Update)
- FDA:FDA Adverse Event Monitoring System (AEMS)
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.